bluebird bio (BLUE) Reports Fiscal Second Quarter 2014 Financial Results
8/13/2014 7:54:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.
"The second quarter of 2014 has been very productive for bluebird bio," said Nick Leschly, chief bluebird. "In June, we presented some very encouraging clinical data on our LentiGlobin product candidate for beta-thalassemia at the EHA conference in Milan, Italy. Also in June, we broadened our technology platform through the acquisition of Pregenen, a gene editing company, and in July we completed a $110 million stock offering, strengthening our balance sheet and allowing us to drive forward all our programs.”
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available.
Help employers find you! Check out all the jobs and post your resume.
comments powered by